Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: Etiological factors or risk markers?

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 164-173

  Lukanova, Annekatrin ^a,b   Becker, Susen ^a,c   Hüsing, Anika ^a   Schock, Helena ^a   Fedirko, Veronika ^d,e   Trepo, Elisabeth ^f   Trichopoulou, Antonia ^g,h   Bamia, Christina ^g   Lagiou, Pagona ^g,i,j   Benetou, Vassiliki ^g   Trichopoulos, Dimitrios ^h,i,j   Nöthlings, Ute ^k,l,m   Tjønneland, Anne ^m   Overvad, Kim ⁿ   Dossus, Laure ^a,o   Teucher, Birgit ^a   Boeing, Heiner ^p   Aleksandrova, Krasimira ^p   Palli, Domenico ^q   Pala, Valeria ^r   Panico, Salvatore ^s   Tumino, Rosario ^t   Ricceri, Fulvio ^u   Bueno De Mesquita, H Bas ^v,w   Siersema, Peter D ^w   Peeters, Petra H M ^w,x   Quiros, Jose Ramon ^y   Duell, Eric J ^z   Molina Montes, Esther ^aa,ab   Chirlaque, Maria Dolores ^ab,ac   Gurrea, Aurelio Barricarte ^ab,ad   Dorronsoro, Miren ^ab   Lindkvist, Björn ^ae   Johansen, Dorthe ^af   Werner, Mårten ^ag   Sund, Malin ^ag   Khaw, Kay Tee ^ah   Wareham, Nick ^ai   Key, Timothy J ^aj   Travis, Ruth C ^aj   Rinaldi, Sabina ^d   Romieu, Isabelle ^d   Gunter, Marc J ^x   Riboli, Elio ^x   Jenab, Mazda ^d   Kaaks, Rudolf ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e EMORY UNIVERSITY   (United States)

^f Centre de Biologie Republique   (France)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h HELLENIC HEALTH FOUNDATION   (Greece)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^k UNIVERSITY OF KIEL   (Germany)

^l UNIVERSITY OF BONN   (Germany)

^m DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

ⁿ Institute of Clinical Medicine   (Denmark)

^o CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^p GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^q CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^r NATIONAL CANCER INSTITUTE   (Italy)

^s UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^t CIVILE M P AREZZO HOSPITAL   (Italy)

^u Human Genetics Foundation   (Italy)

^v NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^w UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^x IMPERIAL COLLEGE LONDON   (United Kingdom)

^y PUBLIC HEALTH DIRECTORATE   (Spain)

^z CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^aa ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^ab CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^ac Murcia Regional Health Authority   (Spain)

^ad INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^ae UNIVERSITY OF GOTHENBURG   (Sweden)

^af LUND UNIVERSITY HOSPITAL   (Sweden)

^ag UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^ah UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ai ADDENBROOKE S HOSPITAL   (United Kingdom)

^aj UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

EPIC; hepatocellular carcinoma; insulin like growth factor I; prospective study; sex hormone binding globulin; testosterone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CANCER RISK; CASE CONTROL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS; HUMAN; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SMOKING; TESTOSTERONE BLOOD LEVEL;

EPIC; HEPATOCELLULAR CARCINOMA; INSULIN-LIKE GROWTH FACTOR I; PROSPECTIVE STUDY; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; ROC CURVE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885949204     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28342     Document Type: Article

References (36)

1. Key TJ, Allen NE, Verkaslo PK, et al. Energy balance and cancer: the role of sex hormones. Proc Nutr Soc 2001; 60: 81-9.
2. Kaaks R, Lukanova A,. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60: 91-106.
3. De Maria N, Manno M, Villa E,. Sex hormones and liver cancer. Mol Cell Endocrinol 2002; 193: 59-63.
4. Scharf JG, Braulke T,. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 11/12: 685-93.
5. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
6. Yu MW, Yang YC, Yang SY, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001; 93: 1644-51.
7. Tanaka K, Sakai H, Hashizume M, et al. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000; 60: 5106-10.
8. Yu MW, Chen CJ,. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53: 790-4.
9. Ganne-Carrie N, Chastang C, Uzzan B, et al. Predictive value of serum sex hormone binding globulin for the occurrence of hepatocellular carcinoma in male patients with cirrhosis. J Hepatol 1997; 26: 96-102.
10. Yuan JM, Ross RK, Stanczyk FZ, et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer 1995; 63: 491-3.
11. Tian Y, Kuo CF, Chen WL, et al. Enhancement of hepatitis B virus replication by androgen and its receptor in mice. J Virol 2012; 86: 1904-10.
12. Kanda T, Steele R, Ray R, et al. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol 2008; 82: 11066-72.
13. Sinclair M, Grossmann M, Gow P, et al. In reference to higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology 2012; 565: 2007.
14. Nguyen HV, Mollison LC, Taylor TW, et al. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern Med J 2006; 36: 362-6.
15. Foresta C, Schipilliti M, Ciarleglio FA, et al. Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Invest 2008; 31: 470-8.
16. Jones JI, Clemmons DR,. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
17. Assy N, Pruzansky Y, Gaitini D, et al. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 2008; 49: 34-42.
18. Colakoglu O, Taskiran B, Colakoglu G, et al. Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol 2007; 18: 245-9.
19. Ormarsdottir S, Ljunggren O, Mallmin H, et al. Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: lack of correlation with bone mineral density. Liver 2001; 21: 123-8.
20. Stuver SO, Kuper H, Tzonou A, et al. Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000; 87: 118-21.
21. Mazziotti G, Sorvillo F, Morisco F, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 2002; 95: 2539-45.
22. Su WW, Lee KT, Yeh YT, et al. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal 2010; 24: 195-200.
23. Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011; 2929: 3892-9.
24. Major JM, Stolzenberg-Solomon RZ, Pollak MN, et al. Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer 2010; 1037: 1089-92.
25. Bingham S, Riboli E,. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004; 4: 206-15.
26. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
27. Trichopoulos D, Bamia C, Lagiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011; 103: 1686-95.
28. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
29. Pencina MJ, D'Agostino RB, Sr, Steyerberg EW,. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
30. Bonefeld K, Moller S,. Insulin-like growth factor-I and the liver. Liver Int 2011; 31: 911-19.
31. Castilla-Cortazar I, Garcia M, Muguerza B, et al. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride- induced cirrhosis. Gastroenterology 1997; 113: 1682-91.
32. Castilla-Cortazar I, Garcia M, Quiroga J, et al. Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology 2000; 31: 592-600.
33. Sobrevals L, Rodriguez C, Romero-Trevejo JL, et al. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010; 51: 912-21.
34. Vera M, Sobrevals L, Zaratiegui M, et al. Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. Gene Ther 2007; 14: 203-10.
35. Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005; 43: 630-6.
36. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.